nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

25.08.2022 | original report

Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment

verfasst von: Sara Dâmaso, MD, Rita Paiva, MD, Inês Pinho, MD, Miguel Esperança-Martins, MD, Raquel Lopes Brás, MD, Cecília Melo Alvim, MD, António Quintela, MD, Ana Lúcia Costa, MD, Luís Costa, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Summary

Background

The link between systemic inflammation and pancreatic cancer is widely accepted. The systemic inflammatory response index (SIRI), based on peripheral neutrophil, monocyte, and lymphocyte counts, emerged recently as a prognostic tool in several types of cancer. The aim of this study is to evaluate the prognostic and predictive value of baseline SIRI in unresectable pancreatic cancer.

Materials and methods

Retrospective analysis of 112 patients with unresectable pancreatic ductal adenocarcinoma (PDAC) followed between 2016 and 2021. Receiver operating characteristic (ROC) curve analysis was used to obtain the optimal SIRI cut-off value, which was set at 1.34.

Results

Univariate analysis showed that SIRI ≥ 1.34 was associated with significantly lower overall survival (OS; p < 0.0001). Multivariate analyses confirmed that SIRI is an independent prognostic factor regardless of first-line chemotherapy regimen (p < 0.0001; hazard ratio [HR] 0.363; 95% confidence interval [CI] 0.223–0.566). Also, patients with SIRI ≥ 1.34 undergoing platinum-based treatment had significantly longer OS than those treated with gemcitabine-based regimens (p = 0.002).

Conclusion

Our study suggests that SIRI is able to predict OS in patients with PDAC. Patients with high SIRI values treated with platinum-based chemotherapy achieved longer OS than those treated with gemcitabine-based regimens.

Vorheriger Artikel Multiple myeloma with central nervous system relapse: a case report

Nächster Artikel Publisher Correction: Brain metastases: new systemic treatment approaches

Orth M, Metzger P, Gerum S, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14(1):1–20. https://doi.org/10.1186/s13014-019-1345-6.CrossRef

Costa PM, Marinho RT, Cortez-Pinto H, et al. Twenty-five years of increasing mortality from pancreatic cancer in Portugal. Pancreas. 2020;43(1):e2–e3.CrossRef

Gao Y, Wang WJ, Zhi Q, et al. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget. 2017;8(51):88835–44. https://doi.org/10.18632/oncotarget.21340.CrossRefPubMedPubMedCentral

Pacheco-Barcia V, Mondéjar Solís R, France T, et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology. 2020;20(2):254–64. https://doi.org/10.1016/j.pan.2019.12.010.CrossRefPubMed

Chen Y, Shao Z, Chen W, et al. A varying-coefficient cox model for the effect of CA19‑9 kinetics on overall survival in patients with advanced pancreatic cancer. Oncotarget. 2017;8(18):29925–34. https://doi.org/10.18632/oncotarget.15557.CrossRefPubMedPubMedCentral

Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19‑9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence-based appraisal. J Gastrointest Oncol. 2012;3(2):105–19. https://doi.org/10.3978/j.issn.2078-6891.2011.021.CrossRefPubMedPubMedCentral

Hoshimoto S, Hishinuma S, Shirakawa H, et al. Validation and clinical usefulness of pre- and postoperative systemic inflammatory parameters as prognostic markers in patients with potentially resectable pancreatic cancer. Pancreatology. 2020;20(2):239–46. https://doi.org/10.1016/j.pan.2019.12.004.CrossRefPubMed

Chen Y, Jiang W, Xi D, et al. Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas. J Investig Med. 2019;67(3):691–8. https://doi.org/10.1136/jim-2018-000801.CrossRefPubMed

Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–67. https://doi.org/10.1002/cncr.30057.CrossRefPubMed

10.

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. https://doi.org/10.1056/NEJMoa1304369.CrossRef

11.

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. https://doi.org/10.1056/NEJMoa1011923.CrossRefPubMed

12.

Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI—Atheromatous affection of arteries. 1858. Nutr Rev. 1989;47(1):23–5. https://doi.org/10.1111/j.1753-4887.1989.tb02747.x.CrossRefPubMed

13.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

14.

Weizman N, Krelin Y, Shabtay-Orbach A, et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene. 2014;33(29):3812–9. https://doi.org/10.1038/onc.2013.357.CrossRefPubMed

15.

Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217–24. https://doi.org/10.1245/s10434-011-1814-0.CrossRefPubMed

16.

Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–4. https://doi.org/10.1002/jso.20329.CrossRefPubMed

17.

Clark EJ, Connor S, Taylor MA, et al. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB. 2007;9(6):456–60. https://doi.org/10.1080/13651820701774891.CrossRefPubMedPubMedCentral

18.

Shirai Y, Shiba H, Sakamoto T, et al. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery. 2015;158(2):360–5. https://doi.org/10.1016/j.surg.2015.03.043.CrossRefPubMed

19.

Li S, Xu H, Wang W, et al. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Cancer Manag Res. 2019;11:3327–37. https://doi.org/10.2147/CMAR.S197911.CrossRefPubMedPubMedCentral

Titel: Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment
verfasst von: Sara Dâmaso, MD
Rita Paiva, MD
Inês Pinho, MD
Miguel Esperança-Martins, MD
Raquel Lopes Brás, MD
Cecília Melo Alvim, MD
António Quintela, MD
Ana Lúcia Costa, MD
Luís Costa, MD
Publikationsdatum: 25.08.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00829-2

Springer Medizin Österreich

Summary

Background

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Molecular profiling leading to personalized cancer treatment

Real time experience applying CAR T-cells for B-cell lymphoma—What we have learned so far: Acute toxicity management

Multiple myeloma with central nervous system relapse: a case report

Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities

CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far

Molecular profiling leading to personalized treatment in breast cancer